Biocon’s subsidiary — Biocon Biologics has acquired R&D capital assets for 60,000 sq. ft. state-of-the-art ‘bench to pilot scale’ Biologics research facility at TICEL Bio Park in Chennai, India. Biocon Biologics has acquired these assets from Pfizer Healthcare India.
The new facility provides Biocon Biologics a significant time advantage in comparison to setting up a Greenfield R&D project and will accelerate the global development of its biosimilars portfolio.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.